Table 6.
Overall survival and progression-free survival from the start of second-line targeted therapy according to progression-free survival on first-line targeted therapy
| Second-line targeted therapy | n | OS | PFS | ||
|---|---|---|---|---|---|
| Median (95% CI) | P | Median (95% CI) | P | ||
| Everolimus | |||||
| PFS1 < 9 months | 230 | 12.7 months (10.5–14.9) | < 0.001 | 5.0 months (3.9–6.1) | < 0.001 |
| PFS1 ≥ 9 months | 290 | 19.7 months (16.4–23.0) | 7.3 months (5.9–8.8) | ||
| Sorafenib | |||||
| PFS1 < 9 months | 123 | 13.8 months (7.9–19.7) | 0.083 | 5.4 months (4.1–6.7) | 0.628 |
| PFS1 ≥ 9 months | 117 | 17.5 months (14.6–20.4) | 6.2 months (5.0–7.4) | ||
| Sunitinib | |||||
| PFS1 < 9 months | 136 | 12.9 months (5.7–20.1) | 0.171 | 5.0 months (4.0–6.0) | 0.571 |
| PFS1 ≥ 9 months | 92 | 15.7 months (9.5–22.0) | 6.9 months (4.0–9.7) | ||
95% CI 95% confidence interval, OS overall survival, PFS progression-free survival, PFS1 progression-free survival on first-line targeted therapy